^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PSMD1 (Proteasome 26S Subunit Non-ATPase 1)

    i
    Other names: PSMD1, Proteasome 26S Subunit Non-ATPase 1, Proteasome (Prosome Macropain) 26S Subunit Non-ATPase 1, 26S Proteasome Non-ATPase Regulatory Subunit 1, 26S Proteasome Regulatory Subunit RPN2, 26S Proteasome Regulatory Subunit S1, 26S Proteasome Subunit P112, P112, Rpn2, S1
    17d
    Covalent targeting of PSMD14 by Eupalinolide B induces oncoprotein degradation and apoptosis in acute promyelocytic leukemia cells. (PubMed, RSC Chem Biol)
    Both genetic knockdown and pharmacological inhibition of PSMD14 recapitulate EB's effects, confirming its essential role in leukemia cell survival and proliferation. Collectively, these findings uncover a previously unrecognized PSMD14-AKT1/CDK4 regulatory axis in leukemia and position EB as a promising chemical probe and lead compound for the development of targeted covalent inhibitors against oncogenic DUBs.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK4 (Cyclin-dependent kinase 4) • CDK7 (Cyclin Dependent Kinase 7) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    20d
    Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma. (PubMed, Blood)
    These findings position PSMD1 as a critical target in cancer therapy, with broad implications for overcoming drug resistance, improving therapeutic outcomes, and potentially impacting immune responses across various cancers. These findings provide a foundation for the clinical development of PSMD1-targeted therapies in myeloma and other malignancies.
    Journal
    |
    PSMD1 (Proteasome 26S Subunit Non-ATPase 1)
    1m
    Identification of immune-related prognostic biomarkers in lung squamous cell carcinoma microenvironment. (PubMed, Front Immunol)
    This study establishes a novel IRGs-based prognostic signature with potential utility for risk stratification and individualized immunotherapeutic strategies in LUSC. Furthermore, it also provides valuable insights into the role of NR1D2 in clinical outcomes.
    Journal • IO biomarker
    |
    PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • NFATC3 (Nuclear Factor Of Activated T Cells 3)
    1m
    PSMD1 inhibition suppresses tumor progression and enhances antitumor immunity by modulating the RTKN/β-catenin/PD-L1 axis in hepatocellular carcinoma. (PubMed, Cell Death Dis)
    This mechanism contributes to HCC progression and the effectiveness of immunotherapy. The PSMD1/RTKN/β-catenin axis could serve as a promising therapeutic target for HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1)
    |
    PD-L1 expression
    2ms
    PSMD11 overexpression promotes epithelial-mesenchymal transition in gastric cancer and affects patient prognosis (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    PSMD11 is overexpressed in gastric cancer and adversely affects patient prognosis likely by driving EMT via activation of the TGF-β/Smad signaling pathway.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • SMAD2 (SMAD Family Member 2)
    3ms
    METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells. (PubMed, Cancer Med)
    These findings demonstrate, for the first time, that METTL14 modulates the expression of genes related to TNF, IFN, IL, and MHC class I in NPC, proposing a novel role for METTL14 in linking inflammation with cancer, a function that has not been fully elucidated.
    Journal
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL7R (Interleukin 7 Receptor) • TNFRSF9 (TNF Receptor Superfamily Member 9) • HLA-B (Major Histocompatibility Complex, Class I, B) • IL32 (Interleukin 32) • CD40LG (CD40 ligand) • IFI16 (Interferon Gamma Inducible Protein 16) • IL1B (Interleukin 1, beta) • IL7 (Interleukin 7) • PSMA2 (Proteasome 20S Subunit Alpha 2) • PSMC6 (Proteasome 26S Subunit, ATPase 6) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • HLA-C (Major Histocompatibility Complex, Class I, C) • METTL14 (Methyltransferase 14) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    4ms
    PSMD11 facilitates immune escape by recruiting USP14 to modulate the deubiquitinating degradation of PD-L1 in non-small cell lung cancer. (PubMed, J Thorac Dis)
    In vivo, the knockdown of PSMD11 promoted the anti-tumor effect of anti-PD-1 therapy. This study showed that PSMD11 recruits USP14 to modulate the deubiquitinating degradation of PD-L1 to promote immune escape in NSCLC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • GZMA (Granzyme A) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • USP14 (Ubiquitin Specific Peptidase 14)
    4ms
    Osimertinib resistance-based immune prognostic related gene signature in EGFR mutant lung adenocarcinoma, in which PSMD11 promotes tumor progression. (PubMed, Transl Lung Cancer Res)
    In addition, PSMD11 could promote the progression of OSI-resistant LUAD by activating the NF-κB/IL-6/STAT3 signaling pathway. This signature has a high predictive effect on the prognosis of OSI-resistant LUAD patients, and can be used as a powerful predictive tool for further selection of chemotherapy and immunotherapy in OSI-resistant LUAD patients.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • G3BP1 (G3BP Stress Granule Assembly Factor 1)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    5ms
    Identification of novel gene fusions in high-grade serous ovarian carcinoma: implications for tumorigenesis and targeted therapy. (PubMed, Cancer Genet)
    This study identified candidate driver fusion genes and suggested new therapeutic targets for HGSOCs.
    Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • AXL (AXL Receptor Tyrosine Kinase) • HDAC1 (Histone Deacetylase 1) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • LATS1 (Large Tumor Suppressor Kinase 1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • CAMKK1 (Calcium/Calmodulin Dependent Protein Kinase Kinase 1) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1) • SH3PXD2A (SH3 And PX Domains 2A) • YY1 (YY1 Transcription Factor) • ZNF143 (Zinc Finger Protein 143)
    |
    TP53 mutation
    6ms
    Serum heat shock protein family A member 9 protein as a biomarker for bortezomib resistance and poor prognosis in patients with multiple myeloma. (PubMed, Anticancer Drugs)
    Higher serum HSPA9 was linked to shorter overall survival rate and independently predicted poor prognosis. Our study demonstrated that elevated serum HSPA9 protein serves as a potential biomarker for bortezomib resistance and poor prognosis in MM patients.
    Journal
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • HSPA9 (Heat Shock Protein Family A (Hsp70) Member ) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14) • TRIM21 (Tripartite Motif Containing 21) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8)
    |
    bortezomib
    6ms
    PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K/AKT/mTOR pathway. (PubMed, Int J Biol Macromol)
    Furthermore, PSMD14 also activated the PI3K/AKT/mTOR pathway and enhanced cellular sensitivity to Cisplatin. Collectively, our findings demonstrate that PSMD14 promotes breast cancer progression through dual mechanisms: deubiquitination of FOXM1 and activation of the PI3K/AKT/mTOR pathway. Thus, PSMD14 represents a potential therapeutic target for breast cancer intervention.
    Journal
    |
    FOXM1 (Forkhead Box M1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14)
    |
    cisplatin
    8ms
    PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1. (PubMed, Front Immunol)
    Mechanistically, PSMD12 interacts with cyclin-dependent kinase 1 (CDK1), preventing its degradation through deubiquitination, thereby accelerating HCC progression by enhancing cell cycle progression. These findings underscore PSMD12's role in HCC and highlight its potential as both a prognostic biomarker and therapeutic target, providing new insights into the molecular mechanisms driving HCC progression.
    Journal
    |
    CDK1 (Cyclin-dependent kinase 1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • PSMD12 (Proteasome 26S Subunit, Non-ATPase 12)